Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer

Publication date: Available online 25 April 2017
Source:Clinical Neurophysiology
Author(s): Tejaswi Kandula, Michelle A. Farrar, Matthew C. Kiernan, Arun V. Krishnan, David Goldstein, Lisa Horvath, Peter Grimison, Frances Boyle, Sally Baron-Hay, Susanna B. Park
Chemotherapy induced peripheral neuropathy (CIPN) is a significant toxicity of cancer treatment, with the potential to affect long-term function and quality of life in cancer survivors. There remains a lack of consensus around optimal assessment techniques. While current approaches to CIPN assessment are focused on clinical grading scales, it is becoming increasingly evident that a more comprehensive multimodal assessment package is necessary to accurately characterise the impact of CIPN as well as gauge the utility of neuroprotective mechanisms. Neurophysiological techniques provide objective biomarkers and may enable early detection of toxicity while patient reported outcomes are necessary to determine the significance of symptoms to individual patients. In addition to providing an objective assessment, clinical neurophysiological techniques provide important insights into the contributory pathophysiological mechanisms of CIPN with different chemotherapy agents.Despite this there is a paucity of implementation of these techniques in the clinical trial setting. This Review aims to facilitate the use of neurophysiological studies as part of comprehensive assessment packages for the monitoring of CIPN by summarising current understanding of neurophysiological changes that underlie the development of neuropathy, clinical presentations and patient reported outcomes as well as advantages and limitations of current techniques for the neurophysiological assessment of CIPN.



http://ift.tt/2pi6dtA